For treatment of mild to moderate Covid-19Roche India today announced that the Central Drugs Standards
Control Organisation (CDSCO) has provided an Emergency Use Authorisation (EUA) for Roche s antibody cocktail (Casirivimab and Imdevimab) in India.
This approval was based on the data that have been filed for the EUA in the United States, and the scientific opinion of the Committee for Medicinal Products for Human Use (CHMP) in the European Union.
This Emergency Use Authorisation will now enable Roche to
import the globally manufactured product batches to India and will be marketed as well as distributed in India through a strategic partnership with Cipla.
Unfounded and without basis : Harsh Vardhan on Chhattisgarh CM s concerns on Covaxin
Chhattisgarh CM had raised two primary concerns regarding Covaxin inhibitions on incomplete trials and absence of expiration date . Dr Vardhan says vaccine approved after due evaluation of pre-clinical and clinical trial data and that expiry date is mentioned on its label
BusinessToday.In | February 12, 2021 | Updated 09:48 IST
Union health minister Harsh Vardhan
Union health minister Harsh Vardhan has written to Chhattisgarh health minister TS Singh Deo, who earlier went public with his government s concerns regarding Bharat Biotech s Covid-19 vaccine, Covaxin. Vardhan said Deo s concerns regarding Covaxin are completely unfounded and without basis .
Vardhan takes on Chhattisgarh minister after state halts Covaxin supplies
Premium
3 min read
Share Via
Read Full Story
Union Health Minister Harsh Vardhan on Thursday took on T S Singh Deo, health minister of Chhattisgarh, who requested to halt supplies of covid-19 vaccine Covaxin to the state citing unavailability of Phase 3 data and also lack of display of expiry date on the vials.
In a scathing reply, the union health minister in a letter said that the opposition party ruled state needs to improve the vaccination coverage among its frontline workers as the adequate supply of “safe and “efficacious vaccines is available with them.
Expert panel recommends emergency use of 2 Covid vaccines in India
426
expert committee today recommended Bharat Biotech’s coronavirus
vaccine “Covaxin” and Serum Institute of India’s “Oxford-AstraZeneca’s
vaccine” for “restricted use in emergency situation in public
interest”.
India (DCGI) on Saturday evening to take the final decision for
“restricted emergency use of vaccine, subject to multiple regulatory
conditionalities”, according to a statement issued by the Indian
Health ministry this evening.
national regulator is scheduled to address the media at 11 am Sunday.
The Subject Expert Committee of Central Drugs Standards Control
Organization (CDSCO) after a two-day meeting concluded today made